3 Dec 2025 • The WHO released its first global guideline on using GLP-1–based therapies for obesity, issuing conditional recommendations for long-term use in adults, excluding pregnant women, based on evidence of clinically meaningful weight loss and metabolic improvement.

The guidance emphasizes combining GLP-1 agents with intensive behavioral interventions, including structured diet and activity programs, to enhance outcomes.

With obesity linked to an estimated 3.7 million deaths in 2024 and global prevalence projected to double by 2030, the WHO cautioned that pharmacotherapy alone will not curb the crisis, urging stronger population-level policies, early-risk screening, and lifelong, person-centered care.

Source: WHO | Read Full Story